Phocas Financial Corp. continued to hold its position in Shire PLC (NASDAQ:SHPG) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,313 shares of the biopharmaceutical company’s stock at the end of the second quarter. Phocas Financial Corp.’s holdings in Shire PLC were worth $217,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also recently bought and sold shares of the stock. Afam Capital Inc. lifted its holdings in Shire PLC by 8.8% in the second quarter. Afam Capital Inc. now owns 29,879 shares of the biopharmaceutical company’s stock valued at $4,938,000 after acquiring an additional 2,410 shares during the period. Dynamic Technology Lab Private Ltd acquired a new stake in Shire PLC in the second quarter valued at $406,000. Verition Fund Management LLC lifted its holdings in Shire PLC by 18.9% in the second quarter. Verition Fund Management LLC now owns 2,967 shares of the biopharmaceutical company’s stock valued at $490,000 after acquiring an additional 472 shares during the period. Sterling Capital Management LLC acquired a new stake in Shire PLC in the second quarter valued at $299,000. Finally, Delphi Management Inc. MA lifted its holdings in Shire PLC by 10.5% in the second quarter. Delphi Management Inc. MA now owns 13,350 shares of the biopharmaceutical company’s stock valued at $2,206,000 after acquiring an additional 1,270 shares during the period. Hedge funds and other institutional investors own 19.24% of the company’s stock.

Shire PLC (NASDAQ SHPG) traded down 3.70% during mid-day trading on Wednesday, reaching $146.43. The company had a trading volume of 1,031,048 shares. Shire PLC has a 12 month low of $139.36 and a 12 month high of $192.64.

Shire PLC (NASDAQ:SHPG) last announced its quarterly earnings data on Friday, October 27th. The biopharmaceutical company reported $3.37 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.66 by ($0.29). Shire PLC had a return on equity of 14.10% and a net margin of 4.70%. Equities analysts expect that Shire PLC will post $14.92 earnings per share for the current year.

The firm also recently disclosed a semiannual dividend, which will be paid on Friday, October 20th. Investors of record on Friday, September 8th will be paid a $0.1527 dividend. This represents a yield of 0.21%. The ex-dividend date of this dividend is Thursday, September 7th. Shire PLC’s dividend payout ratio is currently 41.07%.

TRADEMARK VIOLATION WARNING: “Phocas Financial Corp. Has $217,000 Holdings in Shire PLC (SHPG)” was first reported by Watch List News and is the property of of Watch List News. If you are viewing this report on another publication, it was illegally copied and republished in violation of US and international copyright & trademark law. The correct version of this report can be accessed at https://www.watchlistnews.com/phocas-financial-corp-has-217000-holdings-in-shire-plc-shpg/1639166.html.

A number of equities research analysts have commented on SHPG shares. Royal Bank Of Canada set a $213.00 target price on Shire PLC and gave the company a “buy” rating in a report on Friday, August 4th. Cantor Fitzgerald set a $222.00 target price on Shire PLC and gave the company a “buy” rating in a report on Saturday, July 1st. BTIG Research reissued a “buy” rating and issued a $242.00 target price on shares of Shire PLC in a report on Monday, July 17th. Stifel Nicolaus reissued a “buy” rating and issued a $245.00 target price on shares of Shire PLC in a report on Wednesday, July 12th. Finally, ValuEngine raised Shire PLC from a “hold” rating to a “buy” rating in a report on Thursday, July 6th. One investment analyst has rated the stock with a sell rating, ten have assigned a hold rating and thirteen have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $220.91.

About Shire PLC

Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.

Institutional Ownership by Quarter for Shire PLC (NASDAQ:SHPG)

Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with Analyst Ratings Network's FREE daily email newsletter.